Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

0.3944 -0.0289 (-6.83%)
Streaming Delayed Price Updated: 1:53 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,232,032
Open 0.3881
Bid (Size) 0.3943 (1,700)
Ask (Size) 0.3944 (2,300)
Prev. Close 0.4233
Today's Range 0.3560 - 0.4445
52wk Range 0.3315 - 3.870
Shares Outstanding 75,993,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill

Performance

YTD
-86.3%
-86.3%
1 Month
-85.2%
-85.2%
3 Month
-87.6%
-87.6%
6 Month
-83.3%
-83.3%
1 Year
-69.7%
-69.7%

More News

Read More
News headline image
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? ↗
Via Stocktwits
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Exploring Gossamer Bio's Earnings Expectations ↗
Via Benzinga
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
This Saia Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
Via Benzinga
News headline image
Gossamer Bio to Present at Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream ↗
Via Stocktwits
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 15, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is Gossamer Bio, Inc. - Common Stock publicly traded?
Yes, Gossamer Bio, Inc. - Common Stock is publicly traded.
What exchange does Gossamer Bio, Inc. - Common Stock trade on?
Gossamer Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gossamer Bio, Inc. - Common Stock?
The ticker symbol for Gossamer Bio, Inc. - Common Stock is GOSS on the Nasdaq Stock Market
What is the current price of Gossamer Bio, Inc. - Common Stock?
The current price of Gossamer Bio, Inc. - Common Stock is 0.3944
When was Gossamer Bio, Inc. - Common Stock last traded?
The last trade of Gossamer Bio, Inc. - Common Stock was at 02/24/26 01:53 PM ET
What is the market capitalization of Gossamer Bio, Inc. - Common Stock?
The market capitalization of Gossamer Bio, Inc. - Common Stock is 29.97M
How many shares of Gossamer Bio, Inc. - Common Stock are outstanding?
Gossamer Bio, Inc. - Common Stock has 30M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.